Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P. van Zyl-Smit RN, et al. Among authors: tillmann hc. J Asthma Allergy. 2023 Jan 20;16:123-134. doi: 10.2147/JAA.S392975. eCollection 2023. J Asthma Allergy. 2023. PMID: 36714049 Free PMC article. Review.
Corrigendum to "Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma" [Pulm. Pharmacol. Therapeut. 70 (2021) 102068].
Buhl R, Nikolaev I, Tillmann HC, Vaidya S, Bartels C, Jain M, Jauernig J, Kerstjens HAM. Buhl R, et al. Among authors: tillmann hc. Pulm Pharmacol Ther. 2022 Jun;73-74:102126. doi: 10.1016/j.pupt.2022.102126. Epub 2022 Apr 11. Pulm Pharmacol Ther. 2022. PMID: 35422377 No abstract available.
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, Brown MS, Kostikas K, Belmore K, Fogel R, Patalano F, Drollmann A, Machineni S, Jones I, Yates D, Tillmann HC. Singh D, et al. Among authors: tillmann hc. Respir Res. 2022 Feb 10;23(1):26. doi: 10.1186/s12931-022-01949-3. Respir Res. 2022. PMID: 35144620 Free PMC article. Clinical Trial.
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC. Brittain D, et al. Among authors: tillmann hc. Adv Ther. 2022 Jun;39(6):2365-2378. doi: 10.1007/s12325-021-02025-w. Epub 2022 Jan 24. Adv Ther. 2022. PMID: 35072888 Free PMC article. Review.
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
Buhl R, Nikolaev I, Tillmann HC, Vaidya S, Bartels C, Jain M, Jauernig J, Kerstjens HAM. Buhl R, et al. Among authors: tillmann hc. Pulm Pharmacol Ther. 2021 Oct;70:102068. doi: 10.1016/j.pupt.2021.102068. Epub 2021 Jul 28. Pulm Pharmacol Ther. 2021. PMID: 34329722 Free article. Review.
Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma.
Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S. Bartels C, et al. Among authors: tillmann hc. Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):487-504. doi: 10.1007/s13318-021-00689-x. Epub 2021 May 22. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34024035 Free PMC article.
47 results